Fluvoxamine-induced hyperglycaemia in a diabetic patient with comorbid depression [1]

International Journal of Neuropsychopharmacology

Volumn 6, Issue 1, 2003, Pages 85-87

  Oswald, Pierre ^a   Souery, Daniel ^a   Mendlewicz, Julien ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FENCLONINE; FLUOXETINE; FLUVOXAMINE; HUMAN INSULIN; HYDRAZINE; ISOPHANE INSULIN; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; PLACEBO; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; CARDIOVASCULAR RISK; CASE REPORT; COMORBIDITY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LETTER; MAJOR DEPRESSION; PRIORITY JOURNAL; RELAPSE; REMISSION; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER; DIABETES MELLITUS; FEMALE; FLUVOXAMINE; HUMANS; HYPERGLYCEMIA; MIDDLE AGED;

EID: 0037346802     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145703003262     Document Type: Letter

References (19)

1. Aleyassine H, Lee SH (1972). Inhibition of insulin release by substrates and inhibitors of monoamine oxidase. American Journal of Physiology 222, 565-569.
2. Amsterdam JD, Maislin G, Gold P, Winokur A (1989). The assessment of abnormalities in hormonal responsiveness at multiple levels of the hypothalamic-pituitary-adrenocortical axis in depressive illness. Psychoneuroendocrinology 14, 43-62.
3. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ (2001). The prevalence of comorbid depression in adults with diabetes. Diabetes Care 24, 1069-1078.
4. Feldman JM (1975). Inhibition of pancreatic islet monoamine oxidase by adrenergic antagonists and ethanol. Endocrine Research Communications 2, 503-520.
5. Goodnick PJ, Henry JH, Buki VMV (1995). Treatment of depression in patients with diabetes mellitus. Journal of Clinical Psychiatry 56, 128-136.
6. Gotto Jr. AM (2002). Management of dyslipidemia. American Journal of Medicine 112 (Suppl. 8A), 10S-18S.
7. Hakanson R, Lundquist I, Rerup C (1967). On the hyperglycaemic effect of dopa and dopamine (1967). European Journal of Pharmacology 1, 114-119.
8. Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B (2000). Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clinical Pharmacology and Therapeutics 68, 435-442.
9. Lear J, Burden AC (1992). Fluoxetine side-effects mimicking hypoglycaemia. Lancet 339, 1296.
10. Leonard BE (2001). The immune system, depression and the action of antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry 25, 767-780.
11. Luna B, Feinglos MN (2001). Drug-Induced Hyperglycemia. Journal of the American Medical Association 286, 1945-1948.
12. Lundquist I, Ekholm R, Ericson LE (1971). Monoamine in the pancreatic islets of the mouse. Diabetologia 7, 414-422.
13. Lustman PJ, Freedland KE, Griffith LS, Clouse RE (2000). Fluoxetine for depression in diabetes: a randomised double-blind placebo-controlled trial. Diabetes Care 23, 618-623.
14. Lustman PJ, Griffith LS, Clouse RE, Freedland KE, Eisen SA, Rubin EH, Carney RM, Mc Gill JB (1997). Effects of nortriptyline on depression and glucose regulation in diabetes: results of a double blind, placebo-controlled trial. Psychosomatic Medicine 59, 241-250.
15. Maes M, Song C, Lin A, De Jong R, Kenis G, Bosmans B, De Meester I, Neels H, Scharpe S (1999). Immune and clinical correlates of psychological stress-induced production of interferon-gamma and IL-10 in humans. In: Plotnikoff NO (Ed.), Cytokines, Stress and Immunity (pp. 106-113). Boca Raton, FL, USA: CRC Press.
16. Nelva A, Guy C, Tardy-Poncet B, Beyens MN, Ratrema M, Benedetti C, Ollagnier M (2000). Bleeding syndromes related to selective serotonin reuptake inhibitors (SSRIs). Seven case reports and literature review. Revue Medecine Interne 21, 152-160.
17. Sheline YI, Freedland KE, Carney RM (1997). How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease? American Journal of Medicine 102, 54-59.
18. Skene DJ, Bojkowski CJ, Arendt J (1994). Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans. British Journal of Clinical Pharmacology 37, 181-186.
19. Yamada J, Sugimoto Y, Inoue K (1999). Selective serotonin reuptake inhibitors fluoxetine and fluvoxamine induce hyperglycemia by different mechanisms. European Journal of Pharmacology 382, 211-215.